• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Association Between Dispatch Complaint and Critical Prehospital Time Intervals in Suspected Stroke 911 Activations in the National Emergency Medical Services Information System, 2012 –2016
Stroke, one of the leading causes of death and disability in the United States (US), is a time sensitive emergency.1 Receiving timely treatment is associated with increased survival and better outcomes.2 –5 For every minute that treatment is delayed, a patient with stroke may lose an estimated 1.9 million neurons, leading to irreversible brain tissue damage long term disability, or death.6 Several studies have demonstrated that treatment with intravenous recombinant tissue-type plasminogen activat or (IV alteplase) can positively affect clinical outcomes when administered within a critical timeframe after ischemic stroke symptom onset.
Source: Journal of Stroke and Cerebrovascular Diseases - December 24, 2021 Category: Neurology Authors: Amena Y. Abbas, Erika C. Odom, Isaac Nwaise Source Type: research

Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States
Although many stroke centers in United States are using intravenous (IV) tenecteplase (TNK) for acute ischemic stroke patients, there is paucity of comparative data between IV TNK and IV alteplase from real-world settings.
Source: Journal of Stroke and Cerebrovascular Diseases - December 6, 2022 Category: Neurology Authors: Adnan I. Qureshi, William I. Baskett, Navpreet K. Bains, Brandi R. French, Farhan Siddiq, Camilo R. Gomez, Chi-Ren Shyu Source Type: research

Network Mapping of Time to Antithrombotic Therapy Among Patients With Ischemic Stroke and Transient Ischemic Attack (TIA)
Conclusion: The proportion of patients receiving antithrombotics within 48 h was higher than previously reported in Australia but remained lower than the standard achieved in North American hospitals. Our process map and network analysis show avenues to shorten the time to antithrombotic.
Source: Frontiers in Neurology - June 7, 2021 Category: Neurology Source Type: research

Tenecteplase for Acute Ischemic Stroke Treatment
Semin Neurol DOI: 10.1055/s-0040-1722722The introduction of thrombolytic therapy in the 1990s has transformed acute ischemic stroke treatment. Thus far, intravenous recombinant tissue plasminogen activator (rt-PA) also known as alteplase is the only thrombolytic proven to be efficacious and approved by the United States Food and Drug Administration. But the thrombolytic agent tenecteplase (TNK) is emerging as a potential replacement for rt-PA. TNK has greater fibrin specificity, slower clearance, and higher resistance to plasminogen activator inhibitor-1 than rt-PA. Hence, TNK has the potential to provide superior lysis wi...
Source: Seminars in Neurology - January 20, 2021 Category: Neurology Authors: Baird, Alison E. Jackson, Richard Jin, Weijun Tags: Review Article Source Type: research

Acute Treatment of Ischemic Stroke
This article outlines the evidence to support intravenous thrombolysis with alteplase and tenecteplase, thrombolysis in the setting of DWI/flair mismatch, endovascular treatment in the 6-hour and 6- to 24-hour window, and the use of telemedicine in acute stroke. Current controversies and ongoing trials within endovascular treatment are also detailed. Case presentations are included to provide clinical context and the application of data to practice.
Source: Neurologic Clinics - November 17, 2021 Category: Neurology Authors: Stephanie Lyden, Jana Wold Source Type: research